Registration - Amendment — BROWNSTEIN HYATT FARBER SCHRECK, LLP for NEUROMOLECULAR PHARMACEUTICALS (2007)

Firm

BROWNSTEIN HYATT FARBER SCHRECK, LLP

Client

NEUROMOLECULAR PHARMACEUTICALS

Income

—

Expenses

—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Marketing of antiviral therapy for the H5N1 Avian Flu virus

Lobbyist	Covered position, as disclosed
JUDY BLACK New	N/A
DAVID PHILLIP COHEN New	N/A
TERESA DYER New	N/A
C SUZANNE MENCER New	N/A
PAMELA SILLARS New	N/A

Medical/Disease Research/Clinical Labs MED

Marketing of antiviral therapy for the H5N1 Avian Flu virus

Lobbyist	Covered position, as disclosed
JUDY BLACK New	N/A
DAVID PHILLIP COHEN New	N/A
TERESA DYER New	N/A
C SUZANNE MENCER New	N/A
PAMELA SILLARS New	N/A

Disaster Planning/Emergencies DIS

Marketing of antiviral therapy for the H5N1 Avian Flu virus

Lobbyist	Covered position, as disclosed
JUDY BLACK New	N/A
DAVID PHILLIP COHEN New	N/A
TERESA DYER New	N/A
C SUZANNE MENCER New	N/A
PAMELA SILLARS New	N/A

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.